Vysis' PathVysion Likely Challenger As Dako's HercepTest Enters Market
This article was originally published in The Gray Sheet
If Vysis' presentation to FDA's Nov. 9 Immunology Devices Panel serves as any indication, the company's pending commercial introduction of the PathVysion HER-2 DNA Probe Kit will be aimed specifically at taking market share from Dako's HercepTest (see related story, p. 13).
You may also be interested in...
Genentech's Herceptin package insert to include use of Vysis' PathVysion fluorescence in situ hybridization (FISH) test should address potential discrepancies in assay results compared with immunohistochemistry (IHC) tests, FDA's Oncologic Drugs Advisory Committee concluded
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.